AvMed

MEDICAL PRIOR AUTHORIZATION/STEP-EDIT REQUEST*

Directions: **The prescribing physician must sign and clearly print name (preprinted stamps not valid) on this request**. All other information may be filled in by office staff; **fax to 1-877-535-1391**. No additional phone calls will be necessary if all information (including phone and fax #s) on this form is correct. **If information provided is not complete, correct, or legible, authorization can be delayed**.

For Medicare Members: Medicare Coverage for outpatient (Part B) drugs is outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals. In addition, National Coverage Determination (NCD) and Local Coverage Determinations (LCDs) may exist and compliance with these policies is required where applicable. They can be found at: https://www.cms.gov/medicare-coverage-database/overview-and-quick-search.aspx. Additional indications may be covered at the discretion of the health plan.

Drug Requested: select **ONE** drug below

❑ **Ocrevus®** (ocrelizumab) **(J2350)**	❑ **Ocrevus Zunovo™** (ocrelizumab/hyaluronidase-ocsq) **(J3590)**

MEMBER & PRESCRIBER INFORMATION: Authorization may be delayed if incomplete.

Member Name: _____

Member AvMed #: _____ **Date of Birth:** _____

Prescriber Name: _____

Prescriber Signature: _____ **Date:** _____

Office Contact Name: _____

Phone Number: _____ **Fax Number:** _____

NPI #: _____

DRUG INFORMATION: Authorization may be delayed if incomplete.

Drug Name/Form/Strength: _____

Dosing Schedule: _____ **Length of Therapy**: _____

Diagnosis: _____ **ICD Code, if applicable:** _____

Weight (if applicable): _____ **Date weight obtained:** _____

❑ Standard Review. In checking this box, the timeframe does not jeopardize the life or health of the member or the member's ability to regain maximum function and would not subject the member to severe pain.

Recommended Dosage:

- **Ocrevus®: IV: 300 mg once on day 1, followed by 300 mg once 2 weeks later; subsequent doses of 600 mg are administered once every 6 months (beginning 6 months after the first 300 mg dose)**
  - Initial dose = 300 billable units (300 mg/10 mL) on day 1 and day 15
  - Subsequent doses = 600 billable units (600 mg) every 6 months
- **Ocrevus Zunovo™: SUBQ:** ocrelizumab 920 mg/hyaluronidase 23,000 units once every 6 months

(Continued on next page)

CLINICAL CRITERIA: Check below all that apply. All criteria must be met for approval. To support each line checked, all documentation, including lab results, diagnostics, and/or chart notes, must be provided or request may be denied.

❑ Diagnosis - Primary Progressive Multiple Sclerosis (MS)

- ❑ Prescriber is a Neurologist
- ❑ Member has a confirmed diagnosis of Primary Progressive MS
- ❑ **For Ocrevus Zunovo™ requests:** Member must have had a trial and failure of Ocrevus® IV **(chart notes documenting treatment failure must be submitted)**

❑ Diagnosis - Relapsing-Remitting MS

- ❑ Prescriber is a Neurologist
- ❑ Member has a confirmed diagnosis of relapsing-remitting MS
- ❑ Member has had at least **ONE (1)** medically documented clinical relapse within the previous 12 months
- ❑ Member has tried and failed at least **ONE (1)** of the following agents **(verified by chart notes or pharmacy paid claims; check each tried)**:

❑ dimethyl fumarate (Tecfidera®)	❑ Glatopa® or glatiramer acetate (Copaxone®)
❑ fingolimod (Gilenya®)	❑ teriflunomide (Aubagio®)

- ❑ **For Ocrevus Zunovo™ requests:** Member must have had a trial and failure of Ocrevus® IV **(chart notes documenting treatment failure must be submitted)**

Medication being provided by: Please check applicable box below.

- ❑ **Location/site of drug administration:** _____

  NPI or DEA # of administering location: _____

  OR

- ❑ **Specialty Pharmacy – Proprium Rx**

For urgent reviews: Practitioner should call AvMed Pre-Authorization Department if they believe a standard review would subject the member to adverse health consequences. AvMed's definition of urgent is a lack of treatment that could seriously jeopardize the life or health of the member or the member's ability to regain maximum function.

*****Use of samples to initiate therapy does not meet step edit/ preauthorization criteria.*****

****Previous therapies will be verified through pharmacy paid claims or submitted chart notes.****

***Approved by the Pharmacy and Therapeutic Committee**: ~~5/18/2017; 7/25/2024;~~ **11/21/2024**
UPDATED/REVISED/REFORMATTED: ~~5/30/2017; 6/30/2017; 8/6/2017; 12/12/2017; 9/28/2018; 3/18/2019; 7/7/2019; 9/24/2019; 6/30/2021; 5/13/2022; 6/4/2022; 6/17/2022; 8/21/2024~~ **12/17/2024**